Close Menu

NEW YORK (360Dx) – Omega Diagnostics Group said today that it has received CE marking for its Visitect CD4 Advanced Disease test for monitoring people living with HIV.

The test uses a cut-off of 200 CD4 cells/mm³ of blood, the point at which patients' immune systems are so weakened by HIV that they are at risk of infection by other life-threatening diseases, Omega said.

Colin King, CEO of the Scottish diagnostics firm, said in a statement that it intends "to provide easy-to-use, clinically relevant CD4 testing to less advantaged communities around the world."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.